Michael Cookson to BCG Vaccine
This is a "connection" page, showing publications Michael Cookson has written about BCG Vaccine.
Connection Strength
0.674
-
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Gu?rin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. J Urol. 2024 Jul; 212(1):74-86.
Score: 0.232
-
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021 01; 22(1):107-117.
Score: 0.183
-
Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy. J Urol. 1992 Sep; 148(3):797-801.
Score: 0.103
-
Advances in diagnosis and treatment of bladder cancer. BMJ. 2024 02 12; 384:e076743.
Score: 0.057
-
Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. Eur Urol Oncol. 2022 Oct; 5(5):505-516.
Score: 0.051
-
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. Eur Urol. 2022 03; 81(3):223-228.
Score: 0.049